Overall response rates by prespecified subgroups*

Analysis limitations

- These analyses are exploratory in nature, and definitive conclusions about efficacy in any particular subgroup or between subgroups should not be drawn due to a high possibility of a false positive
- · Numbers may not be available in the Prescribing Information

	Patients With Objective Response (n)	Evaluable Patients (n)		ORR (95% CI)
Overall	58	68	—	85.3 (74.6, 92.7)
Age, years ≥65 <65 ≥75 <75	42 16 13 45	49 19 13 55		85.7 (72.8, 94.1) 84.2 (60.4, 96.6) 100 (75.3, 100) 81.8 (69.1, 90.9)
Sex Female Male	16 42	17 51		94.1 (71.3, 99.9) 82.4 (69.1, 91.6)
Prior HSCT No Yes	40 18	46 22		87 (73.7, 95.1) 81.8 (59.7, 94.8)
Response to last therapy Refractory Relapsed	38 20	47 21	—	80.9 (66.7, 90.9) 95.2 (76.2, 99.9)
CNS disease status Yes No	6 52	7 61		85.7 (42.1, 99.6) 85.2 (73.8, 93.0)
Chemotherapy response Sensitive Refractory	44 14	50 18		88 (75.7, 95.5) 77.8 (52.4, 93.6)
Ki-67 proliferation index <30% ≥30%	8 46	11 52	• • •	72.7 (39.0, 94.0) 88.5 (76.6, 95.6)
TP53 mutation status Yes No Indeterminate	13 26 1	17 29 2		76.5 (50.1, 93.2) 89.7 (72.6, 97.8) 50 (1.3, 98.7)
Blastoid morphology Yes No	16 35	20 39		80 (56.3, 94.3) -1 89.7 (75.8, 97.1)
Bridging Yes No	37 21	44 24		84.1 (69.9, 93.4) 87.5 (67.6, 97.3)
			0 10 20 30 40 50 60 70 80 90 ORR (95% CI)	100

^{*}ORR was defined as the percentage of patients with BOR of either CR or PR after Breyanzi® infusion, as determined by an IRC using 2014 Lugano classification.¹

BOR, best overall response; CI, confidence interval; CR, complete response; HSCT, hematopoietic stem cell transplantation; IRC, Independent Review Committee; ORR, overall response rate; PR, partial response; *TP53*, tumor protein 53.